SUMMARY Verapamil has been used clinically as an antiarrhythmic and antianginal agent. However, the intrinsic negative inotropic properties of verapamil could preclude its use in patients with coronary artery disease concurrently receiving #-adrenergic blocking agents. To investigate this possibility, 20 patients with coronary artery disease and normal left ventricular function receiving chronic propranolol therapy were given i.v. verapamil (0.025, 0.05, or 0.1 mg/kg over 2 minutes, followed by 0.005 mg/kg/min infusion) and the hemodynamic and angiographic effects were studied. The mean (± SD) plasma verapamil concentration at the time the hemodynamic effects were being measured was 122 ± 51 ng/ml for the 10 patients who received low doses (0.025 or 0.05 mg/kg) and 214 ± 108 ng/ml for the 10 patients who received high doses (0.1 mg/kg). Verapamil reduced mean arterial pressure by 22% (p < 0.001), systemic vascular resistance by 24% (p < 0.001), mean pulmonary artery pressure by 16% (p < 0.01), and pulmonary vascular resistance by 23% (p < 0.001) in all 20 patients. Concomitant increases in cardiac index, mean velocity of circumferential fiber shortening, and ejection fraction (due to the unloading effect of verapamil) were not observed. These results were not significantly different between the two dosage levels.
VERAPAMIL is a papaverine derivative first introduced as a coronary vasodilator but subsequently found to have multiple effects on the cardiovascular system. The drug has been used clinically as an antianginal,' antiarrhythmic2 and antihypertensive agent. 3 The pharmacologic properties of verapamil have been related to its selective blockade of the slow channel of the cell membrane by the interference with the transmembrane calcium influx.-Concern that the negative inotropic properties of verapamil may preclude its use in patients with significant coronary artery disease was recently dispelled,4 but concern persists that the intrinsic negative inotropic effect of verapamil may preclude its use in cardiac patients concurrently receiving 3-adrenergic blocking agents. ' This study was undertaken to examine the effects of i.v. verapamil in patients receiving chronic treatment with propranolol for coronary artery disease. This study was designed to identify changes in left ventricular (LV) performance in such patients and to assess the cardiovascular effects of verapamil in commonly accepted therapeutic doses.
Materials and Methods

Study Patients
Twenty consecutive patients with chronic stable angina who were taking at least 40 mg/day of oral propranolol were evaluated. All had angiographically documented coronary artery disease. Their clinical profiles are presented in table 1. The protocol was approved by the Human Subjects Committee of the University of Miami School of Medicine. All patients gave written informed consent. They underwent routine diagnostic cardiac catheterization studies, which included complete left and right hemodynamic evaluation, selective left ventriculography and selective coronary arteriography. All patients were in normal sinus rhythm. None had systemic hypertension, significant valvular or congenital heart defects or clinical evidence of congestive heart failure. Patients with clinically significant renal or hepatic disease, electrolyte imbalance, left bundle branch block, systolic blood pressure below 90 mm Hg, or recent myocardial infarction (within the last 2 months) were excluded from the study.
Except for propranolol and sublingual nitroglycerin, cardiovascular medications were discontinued at least 10 days before catheterization. Nitroglycerin was not required for at least 24 hours before cardiac catheterization in any patient. All patients continued to receive propranolol therapy up to and including the day of the study.
Study Protocol
The study design is illustrated in figure 1 . After the first left ventriculogram and coronary arteriography, patients 1-5 received 0.025 mg/kg, patients 6-10 0.050 mg/kg, and patients 11-20 0.1 mg/kg of verapamil intravenously as a short infusion over a 2-minute period. Immediately after the infusion, a longer i.v. infusion of 0.005 mg/kg/min was started using a Harvard infusion pump and continued for a maximum of 60 minutes. Forty-five minutes after the first ventriculogram, a second left ventriculogram was performed during the verapamil infusion. The elapsed time between the first and second ventriculograms was allowed to eliminate the pharmacologic effects of the contrast medium on myocardial contractility" and to avoid transient reactive hyperemia after coronary arteriography on myocardial contractility. 7 Both selective left ventriculograms were performed using a #7F Cordis pigtail catheter positioned in the left ventricle. Forty-five milliliters of 76% meglumine sodium diatrizoate (Renografin-76) were injected over a 3-second interval. Left ventriculograms in 300 right anterior oblique position were recorded at 60 frames/ sec on 35-mm Kodak CFS film (Estar AH base) with a Siemen 6-inch image intensifier. Only the first four beats after complete opacification were analyzed. If an isolated premature ventricular complex was detected, the third normal sinus beat after the premature complex was selected for analysis.
Volumetric Analysis
A modification of the area-length method8 was used to analyze all LV volumes. End-diastolic volume index (EDVI), end-systolic volume index (ESVI), stroke volume index (SVI), and ejection fraction (EF = SVI/EDVI) were calculated for each patient.
Hemodynamic Measurements
Cardiac output (CO), arteriovenous oxygen difference, and pressure data were collected just before each ventriculogram. CO was determined using the Fick method. All pressures -aortic (AP) and pulmonary artery (PAP); systolic, diastolic, and mean; right and left ventricular systolic and end-diastolic; mean right atrial (RAP); and mean pulmonary capillary wedge (PCWP) -were measured using a Statham (model P23Db) strain gauge and recorded with an Electronics for Medicine DR-12 Simultrace over three full respiratory cycles. After a 10-minute control period, systemic pressure was recorded at 2, 4, 6, 8, 10 and 15 minutes and then every 5 minutes after the short verapamil infusion. Heart rate was monitored and recorded throughout the study and rhythm strips were taken before verapamil administration and at 2, and 60 minutes after the short infusion. Verapamil was quantitated by the gas-liquid chromatography method.10 Blood samples were drawn for plasma propranolol measurements immediately before and at 5 and 30 minutes after the 2-minute infusion and measured by a high-pressure liquid chromatographic assay." This assay has a lower sensitivity level of 5-10 ng/ml and an accuracy of about 2% within the range 50-250 ng/ml. The coefficient of variation is less than 5%.
Statistical Analysis
The results were analyzed using the t test for matched pairs. One-way analysis of variance for repeated measurements was used to compare data from the patients who received 0.025 or 0.050 mg/kg with those from patients who received 0.1 mg/kg. Values are mean + SD.
Results
Drug Dosage and Plasma Concentrations
All patients received propranolol for at least 4 weeks before the study and the average daily dose was 160 ± 92 mg/day. The dose of verapamil administered during the 2-minute infusion ranged from 1.7-8.4 mg (mean 4.9 ± 2.2 mg). The mean total dose of verapamil was 21.6 ± 6.3 mg. Because the 2-minute infusion resulted in less than 1 mg difference in the total dose of verapamil administered to the first five patients (18 mg) vs the second five patients (18.7 mg), these 10 patients were combined as a low-dose group. The average total dose was 18.3 ± 4.6 mg in the lowdose group and 24.8 ± 6.3 mg in the high-dose group (p < 0.05).
Regression analysis was performed to determine if a correlation existed between verapamil plasma concentrations and changes in hemodynamic measurements. No correlation was demonstrated with any of the hemodynamic measurements; specifically, the changes in mean aortic pressure, SVR, cardiac index (CI) and EF had correlation coefficients of less than 0.1 .* Figure 2 shows the time course of mean verapamil plasma levels for all 20 patients. Mean verapamil plasma concentrations ranged from 79.5 ng/ml 5 minutes after the short infusion to 163.5 ng/ml 60 minutes later. The mean plasma verapamil levels at the time the hemodynamic effects were being measured ranged from 122 ± 51 ng/ml for the low-dose group to 214 ± 108 ng/ml for the high-dose group. Mean plasma propranolol levels ranged from 65.7-81.7 ng/ml. VOL 65, No 4, APRIL 1982 subject variation in plasma verapamil levels was observed. The plasma levels of both verapamil'9 20 and propranolol2' were consistent with those reported to be clinically effective.
Intravenous verapamil at the doses used in the present study was found to produce statistically significant decreases in mean AP and mean PAP, with concomitant decreases in SVR and PVR. The decrease in AP is a result of the direct relaxant effect of verapamil on the smooth muscle of arterial walls, which has been demonstrated in both animal studies"3 and man. '4 As in previous hemodynamic studies in which i.v. verapamil was administered alone,4 14 we observed no significant changes in heart rate when verapamil was administered in the presence of chronic propranolol therapy.
Myocardial Although our study group was small, our results are relevant to the question of whether i.v. verapamil can be used safely in cardiac patients concurrently receiving propranolol. Our findings confirm that verapamil is a powerful peripheral vasodilator as judged by a significant reduction in mean AP and SVR. The magnitude of hemodynamic alterations was comparable with that previously reported.4 14 25 Nevertheless, the expected increases in CI, EF and Vcf due to the unloading effect of verapamil appeared to be offset almost completely by some myocardial interaction of the two drugs. Despite this interaction, a measurable depressant effect on contractility could not be detected because Cl, EF and Vcf did not decrease significantly.
Two conditions may limit the general applicability of our results. First, all of the patients in the present series had basal EFs greater than 40%. Consequently, a reduction in CI and left ventricular performance indexes might have occurred in patients with lower EF. Second, all hemodynamic measurements were done in patients in normal sinus rhythm.
As demonstrated by Ryden and Saetre,"5 however, there are differences in the hemodynamic effects of verapamil in patients with chronic atrial fibrillation. Moreover, recent work by Urthaler and James29 demonstrated that the AV junction becomes increasingly more vulnerable to verapamil when either A receptors are blocked or local catecholamine stores are depleted. Detrimental effect of this drug combination may therefore be more evident in patients with chronic atrial fibrillation or in patients with congestive heart failure, a condition in which catecholamine stores are decreased.
Both verapamil and propranolol may be considered valuable therapeutic agents in the treatment of angina pectoris and supraventricular arrhythmias. Because their mode of action is different, it may be appropriate to use these drugs in combination. Our data from patients with good LV function indicate that the combined negative inotropic properties of verapamil and propranolol are of negligible importance. Verapamil can apparently be given relatively safely in patients receiving propranolol without clinical evidence of congestive heart failure. However, the lack of the expected improvement in LV performance due to the unloading effect of verapamil suggests some myocardial depressant interaction of the two drugs. Therefore, when the LV EF is moderate to severely depressed, i.v. verapamil should be used cautiously in patients concurrently taking f-adrenergic blockers, because the combined myocardial depressant action may become clinically manifest.
